Sweden Cancerome Analysis Network - Breast : Genomic Profiling of Breast Cancer
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- 10000
Summary
- Conditions
- Breast Neoplasms
- Type
- Observational
- Design
- Observational Model: CohortTime Perspective: Prospective
Participation Requirements
- Age
- Younger than 125 years
- Gender
- Both males and females
Description
Breast cancer exhibits significant molecular, pathological, and clinical heterogeneity. Current patient and clinicopathological evaluation is imperfect for predicting outcome, which results in overtreatment for many patients, and for others, leads to death from recurrent disease. Therefore, addition...
Breast cancer exhibits significant molecular, pathological, and clinical heterogeneity. Current patient and clinicopathological evaluation is imperfect for predicting outcome, which results in overtreatment for many patients, and for others, leads to death from recurrent disease. Therefore, additional criteria are needed to better personalize care and maximize treatment effectiveness and survival. The Sweden Cancerome Analysis Network - Breast (SCAN-B) study was initiated in 2010 as a multicenter prospective population-based observational study with longsighted aims to analyze breast cancers with next-generation genomic technologies for translational research and integrated with healthcare; decipher fundamental tumor biology from these analyses; utilize genomic data to develop and validate new clinically-actionable biomarker assays; and establish real-time clinical implementation of molecular diagnostic, prognostic, and predictive tests. In the first phase, we focus on molecular profiling by next-generation RNA-sequencing. Gene expression profiles, mutational profiles, and transcript isoform-level data will be analyzed in the context of patient information, clinicopathological variables, and outcome, with the purpose to develop new molecular diagnostic assays for breast cancer. Additional genome-scale RNA, DNA, and protein analyses will be performed in the future. As of June 2020, over 15,000 patients have enrolled in the study, representing approximately 85% of all eligible patients within the catchment region. Tissue and blood collection is integrated within healthcare routines and clinical information is provided from national quality registries.
Tracking Information
- NCT #
- NCT02306096
- Collaborators
- South Sweden Breast Cancer Group
- Mrs. Berta Kamprad Foundation
- U-CAN
- Investigators
- Study Director: Åke Borg, PhD Lund University Principal Investigator: Cecilia Hegardt, PhD Lund University Principal Investigator: Christer Larsson, PhD Lund University Principal Investigator: Niklas Loman, MD, PhD Skane University Hospital Study Chair: Martin Malmberg, MD, PhD Skane University Hospital Principal Investigator: Anna Ehinger, MD Skane University Hospital Principal Investigator: Lisa Rydén, MD, PhD Skane University Hospital Principal Investigator: Lao H Saal, MD, PhD Lund University